Milan, Italy – April 13, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and
Milan, Italy, March 16, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID)
Milan, Italy – March 15, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5),
Final study data intended to support the initiation of Newron’s planned phase III pivotal trial program for evenamide
Milan, Italy and Morristown, NJ, USA, January 21, 2021 -
Milan, Italy, September 15, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
- All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021
- In advanced
Milan, Italy and Morristown, NJ, USA - May 29, 2020 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
Pivotal trial did not meet primary or secondary efficacy variables
Newron will prioritize its Phase III development program of Evenamide in schizophrenia and evaluate additional
Milan, Italy – April 29, 2020 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
